Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Moodys
Dow
Colorcon
QuintilesIMS
US Department of Justice
Cerilliant
McKinsey
Chinese Patent Office

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOMATROPIN RECOMBINANT

« Back to Dashboard

Clinical Trials for Somatropin Recombinant

Trial ID Title Status Sponsor Phase Summary
NCT00006143 Growth Hormone Treatment of Children With HIV-Associated Growth Failure Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00006143 Growth Hormone Treatment of Children With HIV-Associated Growth Failure Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00050921 Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Somatropin Recombinant

Condition Name

Condition Name for Somatropin Recombinant
Intervention Trials
Growth Hormone Disorder 24
Growth Hormone Deficiency 20
Adult Growth Hormone Deficiency 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Somatropin Recombinant
Intervention Trials
Dwarfism, Pituitary 58
Endocrine System Diseases 36
Dwarfism 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Somatropin Recombinant

Trials by Country

Trials by Country for Somatropin Recombinant
Location Trials
United States 219
France 26
Japan 25
Germany 23
China 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Somatropin Recombinant
Location Trials
New York 14
California 12
Texas 12
Massachusetts 12
Ohio 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Somatropin Recombinant

Clinical Trial Phase

Clinical Trial Phase for Somatropin Recombinant
Clinical Trial Phase Trials
Phase 4 20
Phase 3 50
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Somatropin Recombinant
Clinical Trial Phase Trials
Completed 90
Terminated 12
Recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Somatropin Recombinant

Sponsor Name

Sponsor Name for Somatropin Recombinant
Sponsor Trials
Novo Nordisk A/S 52
Pfizer 13
Eli Lilly and Company 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Somatropin Recombinant
Sponsor Trials
Industry 125
Other 52
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
US Army
Fuji
Dow
Covington
Healthtrust
Chubb
Citi
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.